Wall Street brokerages predict that Inogen Inc (NASDAQ:INGN) will report sales of $107.55 million for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Inogen’s earnings. The highest sales estimate is $110.68 million and the lowest is $104.10 million. Inogen posted sales of $97.24 million during the same quarter last year, which would indicate a positive year over year growth rate of 10.6%. The company is scheduled to report its next earnings results on Tuesday, August 6th.

According to Zacks, analysts expect that Inogen will report full-year sales of $409.24 million for the current fiscal year, with estimates ranging from $407.57 million to $411.30 million. For the next financial year, analysts anticipate that the firm will post sales of $470.86 million, with estimates ranging from $458.56 million to $482.90 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Inogen.

Inogen (NASDAQ:INGN) last announced its earnings results on Tuesday, May 7th. The medical technology company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.05). The business had revenue of $90.20 million for the quarter, compared to the consensus estimate of $89.69 million. Inogen had a return on equity of 15.59% and a net margin of 12.56%. Inogen’s revenue for the quarter was up 14.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.48 EPS.

Several equities analysts have recently issued reports on the company. BidaskClub raised Inogen from a “strong sell” rating to a “sell” rating in a research note on Wednesday. Stifel Nicolaus cut their target price on Inogen from $160.00 to $85.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. JPMorgan Chase & Co. lowered Inogen from an “overweight” rating to a “neutral” rating and cut their target price for the company from $175.00 to $72.00 in a research note on Wednesday, May 8th. Needham & Company LLC cut their target price on Inogen from $191.00 to $111.00 and set a “strong-buy” rating on the stock in a research note on Wednesday, May 8th. Finally, ValuEngine lowered Inogen from a “hold” rating to a “sell” rating in a research note on Thursday, February 28th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. Inogen presently has a consensus rating of “Hold” and an average target price of $121.60.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in INGN. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Inogen by 9.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,276 shares of the medical technology company’s stock valued at $158,000 after buying an additional 112 shares in the last quarter. Advisors Asset Management Inc. boosted its holdings in shares of Inogen by 91.6% in the 4th quarter. Advisors Asset Management Inc. now owns 2,462 shares of the medical technology company’s stock valued at $306,000 after buying an additional 1,177 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of Inogen by 52.4% in the 4th quarter. Rhumbline Advisers now owns 52,759 shares of the medical technology company’s stock valued at $6,551,000 after buying an additional 18,131 shares in the last quarter. SG Americas Securities LLC boosted its holdings in shares of Inogen by 6.1% in the 4th quarter. SG Americas Securities LLC now owns 8,368 shares of the medical technology company’s stock valued at $1,039,000 after buying an additional 479 shares in the last quarter. Finally, First Mercantile Trust Co. acquired a new position in shares of Inogen in the 4th quarter valued at $99,000. 98.63% of the stock is currently owned by institutional investors.

Shares of INGN stock traded up $1.54 during trading hours on Thursday, hitting $72.67. 441,851 shares of the company’s stock were exchanged, compared to its average volume of 600,306. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.70 and a current ratio of 7.35. The stock has a market capitalization of $1.56 billion, a PE ratio of 31.18, a PEG ratio of 2.80 and a beta of 1.58. Inogen has a 52 week low of $62.31 and a 52 week high of $287.79.

About Inogen

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Further Reading: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Get a free copy of the Zacks research report on Inogen (INGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.